A double-blind, randomized phase 3b trial called ATTAIN-MAINTAIN examined orforglipron for maintaining body weight reduction. The study appears in Nature. This research focuses on sustaining weight loss achieved earlier.
Orforglipron serves as the main treatment in a clinical study aimed at maintaining body weight reduction. Participants in this trial seek to hold onto weight loss after initial reduction. The investigation centers on how well orforglipron supports long-term weight control.
The phase 3b ATTAIN-MAINTAIN trial provides key data on this approach. It follows standard late-stage testing protocols for drugs like orforglipron. Researchers designed it to assess sustained effects on body weight.
This trial uses a double-blind format, where neither participants nor researchers know who receives orforglipron or placebo. Randomization ensures fair group assignment. Such methods help confirm reliable outcomes for weight maintenance.
The randomized element divides participants into groups by chance. This setup reduces bias in results. Double-blind and randomized features make the ATTAIN-MAINTAIN trial a strong test of orforglipron's role.
Orforglipron targets body weight reduction maintenance specifically. As a phase 3b study, ATTAIN-MAINTAIN builds on earlier trials. It refines understanding of the drug in real-world weight management scenarios.
Phase 3b trials often expand on phase 3 findings. Here, the focus stays on keeping weight off post-loss. Orforglipron's performance in this context forms the core of the research.
Peptides referenced: Orforglipron.
Related reading: Orforglipron and Probiotic Aid Weight Loss Maintenance in Obesity, Daily Pill Could Tackle Dreaded Ozempic Rebound, Oral Orforglipron Effective for Obese Older Adults, Study: Orforglipron Maintains Most Weight Loss from Injectables.